Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NELMAS: Lutathera vs Best Supportive Care as Adjuvant Treatment for Neuroendocrine Liver Metastases
NCT05987176Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), liver metastases, sponsored by Imperial College London. Started Aug 2024; status: terminated.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)liver metastases
Beyond the preview
Go deeper on NCT05987176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987176.